Archive

January 12, 2025

Browsing

S&P 5850 has been the most important “line in the sand” for stocks since the pullback from the 6000 level in November 2024. With the SPX closing below that 5850 level on Friday, we see further corrective pressures with the 200-day moving average as a reasonable downside target. Today, we’ll break down a series of projection techniques that have helped us hone in on this potential area of support.

The Break of 5850 Completes a Head-and-Shoulders Top

One of the most widely-followed patterns in technical analysis, the fabled head-and-shoulders topping pattern, is formed by a major high surrounded by lower highs on each side. After the S&P 500 established a lower high in December, we immediately started looking for confirmation of this bearish pattern.

To confirm a head-and-shoulders top, and initiate downside targets on a chart, the price needs to break through the “neckline” formed by the swing lows between the head and two shoulders. While price pattern purists may advocate for a downward-sloping trendline to capture the intraday lows of the neckline, I’ve been focused on the price level of SPX 5850. As long as the S&P remained above that level of support, then the market could still be considered in a healthy bullish phase. But a close below the 5850 level on Friday tells me that this corrective move may just be getting started.

Let’s consider some ways to identify a potential downside objective, first using the pattern itself.

Calculating a Minimum Downside Objective

As delineated in Edwards and Magee’s classic book on price patterns, you can use the height of the head-and-shoulders pattern to identify an initial downside objective. Basically, take the distance from the top of the head to the neckline, and then subtract that value from the neckline at the breaking point.

Based on my measurements on the S&P 500 chart, this process yields a downside target of right around 5600. It’s worth noting that Edwards and Magee considered this a “minimum downside objective”, implying that there certainly could be further deterioration after that point has been reached.

Now let’s consider some other technical analysis tools that could help us to validate this potential downside target.

A Confluence of Support Confirms Our Measurement

If we create a Fibonacci framework using the August 2024 low and the December 2024 high, we can see a 38.2% retracement around 5725, which lines up fairly well with the swing low from late October. Perhaps this could serve as a short-term support level during the next downward phase?

As I review the chart, however, I’m struck by the fact that the 50% retracement lines up almost perfectly with our price pattern objective. Many early technical analysts, including the infamous W.D. Gann, favored the 50% retracement level as the most meaningful to watch.

You may also notice that the 200-day moving average is gently sloping higher, rapidly approaching our “confluence of support” around 5600. Given the agreement between multiple technical indicators on this price point, we consider it the most likely downside target given this week’s breakdown.

I would also point that while I feel that identifying price targets can be a helpful exercise, as it gives you a framework with which to evaluate further price action, the most important signals usually come from the price itself. How the S&P 500 would move between current levels and 5600 may tell us a great deal about the likelihood of finding support versus a more bearish scenario in the coming weeks.

RR#6,

Dave

P.S. Ready to upgrade your investment process? Check out my free behavioral investing course!


David Keller, CMT

President and Chief Strategist

Sierra Alpha Research LLC


Disclaimer: This blog is for educational purposes only and should not be construed as financial advice. The ideas and strategies should never be used without first assessing your own personal and financial situation, or without consulting a financial professional.

The author does not have a position in mentioned securities at the time of publication. Any opinions expressed herein are solely those of the author and do not in any way represent the views or opinions of any other person or entity.

The markets extended their decline over the past five sessions and ended the week on a negative note. While the week started on a bearish note, the Nifty violated a few key levels on higher and lower time frame charts. Along with the weak undercurrent, the trading range widened again as the Nifty moved in a 745-point range. The volatility spiked up, and India Vix surged 10.16% to 14.91 on a weekly basis. Following a thoroughly bearish undertone, the headline index closed with a net weekly loss of 573.25 points (-2.39%).

The week that has gone by has remained important from a technical perspective. The Nifty started the week by violating the 200-DMA placed at 23940 and has closed significantly below this crucial level. On the weekly charts, the Nifty has breached another critical level of 50-week MA, currently at 23659. In the process, the Nifty has dragged its resistance points lower; any technical rebound will find resistance at this point. It is important to note that the 50-week MA has been violated after three retests, and the breach of this level will have bearish considerations for the markets. Unless the Nifty crosses above this level again, it will stay vulnerable to a prolonged phase of weakness.

Monday is likely to see the Nifty beginning on a soft note; the levels of 23650 and 23880 are likely to act as resistance points. The supports come in at 23300 and 23050 levels.

The weekly RSI is 43.53; it has marked a new 14-period low, which is bearish. The RSI also shows a bearish divergence against the price. The weekly MACD is bearish and stays below the signal line. The widening Histogram hints at accelerated momentum on the downside.

The pattern analysis of the weekly chart shows Nifty completing a painful process of mean reversion by finding support at the 50-week MA in November. Since then, it has retested this level three times and has breached it by closing below this crucial level. The 50-week MA is placed at 23659; so long as the Index stays below this point, it remains vulnerable to an extended period of weakness in the near term.

Over the past week, the technical developments have created a strong resistance zone for the Nifty between 23650-24000 level. So long as the Index stays below this zone, it will likely trade with a weak undercurrent. Given the current technical setup, cutting down on leveraged exposures and keeping them at modest levels is extremely important. While initiating fresh exposures, staying in the stocks with strong or improving Relative Strength will be necessary as that would provide resilience to the investments. While staying highly selective, a highly cautious outlook is recommended for the coming week.


Sector Analysis for the coming week

In our look at Relative Rotation Graphs®, we compared various sectors against CNX500 (NIFTY 500 Index), which represents over 95% of the free float market cap of all the stocks listed.

Relative Rotation Graphs (RRG) show that Nifty Bank, Services Sector, Nifty Financial Services, and Nifty IT indices are inside the leading quadrant. Barring the Nifty IT index, all others are seen giving up on their relative momentum. The Nifty Midcap 100 has rolled inside the leading quadrant and may relatively outperform the broader markets.

The Nifty Pharma Index stays inside the weakening quadrant.

The Nifty Metal Index has rolled inside the lagging quadrant. Along with the Media, PSE, Energy, and Commodities, it is likely to underperform the broader markets relatively. The Infrastructure, Auto, FMCG, and Consumption Indices are in the lagging quadrant but are improving their relative momentum against the broader markets.

The Nifty Realty index is well placed inside the improving quadrant. The PSU Bank Index is also inside the improving quadrant, but it is seen paring its relative momentum against the broader markets.


Important Note: RRG charts show the relative strength and momentum of a group of stocks. In the above Chart, they show relative performance against NIFTY500 Index (Broader Markets) and should not be used directly as buy or sell signals.  


Milan Vaishnav, CMT, MSTA

Consulting Technical Analyst

www.EquityResearch.asia | www.ChartWizard.ae

The stock market is in pullback mode with the S&P 500 EW ETF down 5.15% over the past month and down 1% year-to-date. This makes it a good time to monitor relative performance and create a relative strength watch list. Stocks and ETFs holding up best during pullbacks often lead when the market regains its footing. Today’s report will show a starter list and analyze the chart for an AI Robotics ETF.

The table below shows 1-month and year-to-date performance for a selection of industry group ETFs. With the S&P 500 EW ETF down on both timeframes, ETFs with gains are holding up well and ETFs with smaller losses show relative strength (less weakness). Five ETFs are up on both timeframes and holding up well in the face of broad market weakness.

Note that this list is simply the first cut. I would make a further cut by insuring that the ETF is in a long-term uptrend. For example, the Clean Energy ETF (PBW) is below its 200-day SMA and would not make the cut. The Medical Devices ETF (IHI) and Robotics AI ETF (ARTY) are in long-term uptrends, and make the cut. Let’s look at ARTY. A recent Chart Trader report/video highlighted the recent breakout in IHI.

The chart below shows ARTY hitting a new high in early December and price above the rising 200-day SMA. ARTY is in a long-term uptrend. There was a big breakout in mid October, an oversold reading in late October and then a 17% run to new highs. ARTY then formed a pennant and broke out with a surge earlier this week, only to fall back the last three days. Overall, I think the pennant breakout is still bullish and this is a throwback to the breakout zone. A break below the pennant lows would negate this pattern and argue for a deeper correction.

Chart Link

The middle window shows the price-relative (ARTY/RSP Ratio) breaking above its 200-day SMA in late November. ARTY shows relative strength and the price-relative hit a new high in early January. The lower window shows %B, which I use to identify oversold conditions within an uptrend. A dip below 0 means the close is below the lower Bollinger Band. This means there was a pullback within the uptrend, which is an opportunity.

I will be following ARTY and other leading ETFs closely in the Chart Trader reports and videos. Our reports warned of the breakout in the 10-yr Treasury Yield in before Christmas (HERE) and we also showed how to distinguish between a robust bounce and a dead cat bounce (HERE).

Click here to take Chart Trader trial and get immediate access.

//////////////////////////////////////////////////

To understand what makes the Dow Jones tick, you have to first understand one of the key differences between the Dow Jones and the S&P 500 indices. There are a few, but none more critical than the following:

Index Weighting

The S&P 500 is market-cap weighted, meaning that companies with the highest market capitalization have a stronger hand in moving the S&P 500 index value. Currently, these are the companies that play the largest role in moving this benchmark index, including their weighting:

  • AAPL – 7.58%
  • NVDA – 6.59%
  • MSFT – 6.27%
  • AMZN – 4.11%
  • GOOGL – 4.02%

These are 5 of the Mag 7 stocks and they carry 28.57% of the entire weighting of the benchmark S&P 500 index. It’s easy to see how the S&P 500 can be swayed easily by the performance of just these 5 stocks.

Well, guess what? We need a cute lil name for the Top 5 price-weighted stocks in the Dow Jones, because their collective weight is 32.43% of the entire Dow Jones Industrial Average. The Dow Jones, by contrast, is a price-weighted index. The highest priced stock carries the most weight, while the lowest priced stock carries the least weight. Market capitalization plays NO role in the weighting. Want to know who the “Fabulous 5” are? Here ya go:

  • GS – 8.25%
  • UNH – 7.29%
  • MSFT – 6.07%
  • HD – 5.60%
  • CAT – 5.22%

All 5 of these stocks now trade beneath their declining 20-day EMAs and only one (MSFT) still shows a 20-day EMA above its 50-day SMA. In other words, 4 of the 5 have experienced “death crosses”, which are bearish technical developments.

Looking at the RRG

Here’s another way to look at the change that’s taken place within the Fabulous 5, just over the past 5-6 weeks. But before we do that, let’s first pull up the chart of the entire Dow Jones:

Heading into December, there was a solid uptrend on the Dow’s absolute chart and mostly sideways relative action after a very strong relative performance in July. Since early December, even late November, everything has headed south on the Dow Jones.

We can now take a look at an RRG as of early December to show how the Fab 5 were leading at that time:

This shows how each of the Fab 5 were performing relative to the benchmark S&P 500. 4 of the 5 were situated on the right side of the chart in the leading or weakening quadrants. This means they were relative leaders. Now, just a handful of weeks later, check out how these 5 stand relative to the S&P 500:

All 5 are currently residing on the left side of this chart, indicative of relative weakness, not strength. Momentum is building in the majority of the companies, so if that continues, we could begin to see relative outperformance of the Dow Jones again. For now, though, caution is the word.

One last thing. I’ve updated my Dow Jones Components ChartList and have numbered them 1 to 30, in price order, which reflects the highest-weighted to lowest-weighted stocks in the Dow Jones. I’m sorting this ChartList based on 1-month performances (SCTR scores are also reflected):

Of the 7 worst 1-month performers, 5 of them are in the Top 7 in terms of market weight. In other words, many of the worst recent performers in the Dow Jones also happen to be among the most heavily-weighted. Also, it’s important to note that many of the top-weighted Dow Jones stocks are also among the worst relative performers, as measured by SCTR scores (StockCharts Technical Rank, a form of relative strength). This combination is what has been crushing the Dow Jones. Until this changes, the Dow Jones will remain under relative pressure vs. the other major indices.

My Favorite Dow Jones Component

There are a number of ways to rank the potential of the various Dow Jones component stocks for 2025 and, obviously, it depends on your criteria. But I’ll be providing my FAVORITE Dow Jones stock (and why) for 2025 in Monday’s EB Digest, our 100% free newsletter. If you’re not already an EB Digest subscriber, and you’d like to check out my pick for 2025, please CLICK HERE and enter your name and email address. Again, it’s completely free and there’s no credit card required!

Happy trading!

Tom

From established players to up-and-coming firms, Canada’s pharmaceutical company landscape is diverse and dynamic.

Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are playing a role in the landscape as well.

Read on to learn about what’s been driving the share prices of the best performing Canadian pharma stocks.

1. NurExone Biologic (TSXV:NRX)

Press ReleasesCompany Profile

Year-over-year gain: 147.27 percent
Market cap: C$34.08 million
Share price: C$0.68

NurExone Biologic is the biopharmaceutical company behind ExoTherapy, a drug delivery platform that uses exosomes, which are nano-sized extracellular vesicles, to create treatments for central nervous system disorders, spinal cord injuries and traumatic brain injuries. It is a less invasive alternative to cell transplantation, which requires surgery and carries the risk of rejection.

NurExone’s first nano-drug, ExoPTEN, uses a proprietary sIRNA sequence delivered with the ExoTherapy platform to treat spinal cord injuries. ExoPTEN received orphan drug designation from the US Food and Drug Administration (FDA) in October 2023, meaning it has been recognized as a potential treatment for rare medical conditions. The designation makes it eligible for incentives such as market exclusivity and regulatory assistance aimed at accelerating its development and approval.

In December 2024, the company released preclinical results from animal testing evaluating the efficacy of its nano-drug ExoPTEN in restoring lost vision. The lead investigator at the Goldschleger Eye Institute, which collaborated on the study, said the results were ‘extremely encouraging,’ and ‘suggest that ExoPTEN could fundamentally change how we approach conditions like glaucoma and optic nerve trauma.’

2. Cipher Pharmaceuticals (TSX:CPH)

Company Profile

Year-over-year gain: 140.88 percent
Market cap: C$377.18 million
Share price: C$14.26

Cipher Pharmaceuticals is a specialty pharma company with a diverse portfolio of treatments, including a range of dermatology and acute hospital care products. The company has out-licensed some of its offerings as well. Cipher began trading on the OTCQX Best Market under the symbol CPHRF in early 2024.

In addition to its current portfolio, Cipher has acquired Canadian rights to CF-101, a dermatology treatment for moderate to severe plaque psoriasis is currently expected to undergo Phase III clinical trials. The company is also conducting proof-of-concept studies on DTR-001, a topical treatment for removing tattoos.

On July 29, Cipher announced it had signed a definitive asset purchase agreement with ParaPRO for its US-based Natroba operations and global product rights, and the news caused Cipher’s share price to spike significantly. The company’s Q3 2024 results showed a product gross margin from the acquired Natroba products of 85 percent.

3. Satellos Bioscience (TSXV:MSCL)

Company Profile

Year-on-year gain: 88.89 percent
Market cap: C$95.99 million
Share price: C$0.85

Satellos Bioscience is a Canadian pharmaceutical company expanding treatment options for muscle disorders. The company has focused specifically on Duchenne muscular dystrophy, developing therapies to regenerate and repair muscle tissue by targeting the specific biological pathways involved. Its lead candidate SAT-3247 targets a protein called AAK1, which regulates the activity of stem cells that activate and differentiate new muscle fibers.

An acceptance to commence Phase 1 clinical trials of the drug was announced on August 19 and the first patient was dosed on September 18. Analysis of tests conducted on canines, shared on October 1, showed improved muscle morphology and increased muscle regeneration with no adverse side effects.

An update was provided in November, revealing it had begun enrolment for a multiple-ascending-dose arm of the Phase 1 study after no drug-related adverse events were reported in the single-ascending-dose group.

4. Telescope Innovations (CSE:TELI)

Press ReleasesCompany Profile

Year-over-year gain:81.4 percent
Market cap: C$20.39 million
Share price: C$0.39

Telescope Innovations is a chemical technology company that develops scalable manufacturing processes and tools that combine robotic automation, online analysis and machine learning for the pharmaceutical and chemical industries.

The company has commercialized its Direct Inject-LC system. Short for Direct Inject Liquid Chromatography, the system combines hardware and software to analyze chemical reactions and can potentially reduce the time and cost of new drug development.

On July 31, Telescope Innovations entered into a collaborative research agreement with pharma giant Pfizer (NYSE:PFE) to accelerate pharmaceutical research and development using automation, robotics and artificial intelligence.

According to a press release, some efforts will focus on deploying Self-Driving Laboratories, a concept pioneered by Telescope Innovations in which robotic systems carry out experiments while AI algorithms analyze the data in real time to inform researchers about what the next steps should be.

5. Medexus Pharmaceuticals (TSX:MDP)

Company Profile

Year-over-year gain: 46.47 percent
Market cap: C$100.34 million
Share price: C$3.94

Medexus Pharmaceuticals specializes in bringing drugs to treat rare diseases to North America. The company manages the entire process through its fully integrated operations, from acquiring and developing drugs to marketing and selling them. Some of its key products include treatments for hemophilia B and rheumatoid arthritis, as well as a line of drugs for autoimmune diseases like lupus and allergy treatments.

In November 2024, Medexus Pharmaceuticals announced it had successfully negotiated with the pan-Canadian Pharmaceutical Alliance to make treosulfan, which Medexus commercialized in Canada under the name Trecondyv, available to publicly funded drug programs and patients. Trecondyv is indicated as part of conditioning treatment prior to bone marrow transplants in patients with certain types of blood cancers.

In addition to Canada, Medexus has the exclusive commercialization rights to treosulfan in the US, where it currently being reviewed by the FDA for approval. The FDA extended the review period for the new drug application for treosulfan in September and set a new prescription drug user fee act target action date of January 30, 2025.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Cybercrime is a growing concern, and it’s estimated that the annual cost of fighting cyber crime will reach US$10.5 trillion by 2025. Cybersecurity companies are working to address the challenge.

The list from eSecurity Planet features 20 privately held and publicly traded cybersecurity companies across a range of stock exchanges. The firm employed criteria such as user reviews, product features and benefits, analyst reports, independent security tests and use cases to evaluate companies in the cybersecurity sector.

The largest cybersecurity companies by market cap shown below are all listed on the NASDAQ and NYSE. Stock data was current as of market close on January 9, 2025.

1. Microsoft (NASDAQ:MSFT)

Company Profile

Market cap: US$3.16 trillion
Share price: US$424.56

The largest cybersecurity company by market cap is Microsoft. The tech giant is a major player in the cloud security market, which includes cloud native application protection platform (CNAPP) products and services. In fact, Microsoft is the largest CNAPP solution provider, according to KeyBanc Capital.

Prominent cybersecurity firm Security Risk Advisors recently became a member of the Microsoft Intelligent Security Association.

2. Broadcom (NASDAQ:AVGO)

Company Profile

Market cap: US$3.16 trillion
Share price: US$424.56

Global technology firm Broadcom has built a large portfolio of embedded and mainframe security solutions, as well as payment authentication software.

The company broadened its offerings with the Symantec Enterprise Cloud in November 2019 with the acquisition of the enterprise software division of Symantec, which has since changed its name to Gen Digital (NASDAQ:GEN). Broadcom’s Symantec offerings include secure access service edge technologies and zero-trust security.

3. Cisco Systems (NASDAQ:CSCO)

Company Profile

Market cap: US$235.78 billion
Share price: US$59.20

For a number of years now, Cisco Systems has increasingly invested in boosting its cybersecurity services. Today, the company offers an array of products for cloud security, endpoint security and security analytics. To address the cybersecurity skills shortage, Cisco offers certification programs for IT professionals.

In response to rising security risks in AI-powered applications, Cisco acquired Robust Intelligence, a company specializing in protecting AI systems from vulnerabilities and attacks, in September 2024.

4. IBM (NYSE:IBM)

Company Profile

Market cap: US$206.36 billion
Share price: US$223.18

IBM’s security division offers customers an advanced and integrated portfolio of enterprise security products and services. IBM X-Force helps businesses and organizations integrate security solutions into their everyday functions and provides help with risk assessment, incident detection and threat response. The company is harnessing the power of AI to combat cybersecurity threats.

In May 2024, IBM announced new X-Force Red testing services that focus on identifying and mitigating vulnerabilities in generative AI applications and models. Like Cisco, IBM also offers cybersecurity certification programs.

5. Palo Alto Networks (NASDAQ:PANW)

Company Profile

Market cap: US$113.41 billion
Share price: US$172.83

Palo Alto Networks bills itself as “the global cybersecurity leader.” The company’s security portfolio includes advanced firewalls and cloud-based offerings that protect more than 80,000 organizations across their clouds, networks and mobile devices.

An example of its more recently launched offerings include Prisma Cloud, which integrates AI across various security domains, including network security, cloud security and security operations. In October 2024, Palo Alto expanded its offerings to the industrial sector.

6. CrowdStrike Holdings (NASDAQ:CRWD)

Company Profile

Market cap: US$88.36 billion
Share price: US$358.72

CrowdStrike Holdings is a software-as-a-service solutions provider. This team of cybersecurity professionals uses advanced endpoint detection and response applications and techniques in its machine-learning-powered antivirus protection offerings to ensure breaches are stopped before they occur.

This is another major cybersecurity company that is incorporating AI, adding it to its security information and event management (SIEM) offerings.

Its new AI-powered functions for its Falcon Next-Gen SIEM platform were first released in May 2024, including the integration of its Charlotte AI. Then, in July, CrowdStrike announced its Falcon Complete Next-Gen MDR service, which incorporates data from its SIEM platform and AI capabilities.

7. Fortinet (NASDAQ:FTNT)

Company Profile

Market cap: US$73.61 billion
Share price: US$96.04

Fortinet provides end-to-end cybersecurity infrastructure products and services, such as firewalls, antivirus tools, intrusion prevention and endpoint security. The company’s cybersecurity platform can address critical security challenges and can protect data across digital infrastructure systems, whether in networked, application, multi-cloud or edge environments. Fortinet’s client base includes major sports teams, including the Vancouver Canucks NHL hockey team and the Pittsburgh Steelers NFL football team.

8. Zscaler (NASDAQ:ZS)

Company Profile

Market cap: US$28.74 billion
Share price: US$187.78

Cloud security company Zscaler’s Zero Trust Exchange platform can be used to secure user-to-app, app-to-app and machine-to-machine communications over any network. The company also offers cloud migrating services. Zscaler is known for setting the standard in the field of security service edge, and it claims the Zero Trust Exchange is the world’s most-used security service edge platform.

In December 2024, the company expanded its partnership with IT services and consulting company Cognizant (NASDAQ:CTSH) as the pair work together to help enterprises address cyber threats by providing an advanced, AI-enabled zero trust cloud security platform.

9. Check Point Software (NASDAQ:CHKP)

Company Profile

Market cap: US$20.15 billion
Share price: US$183.19

Check Point Software is part of the unified threat management sector, and it offers a wide variety of products to protect users on mobile, networks and the cloud. It also provides users with various security management services to prevent future cyber attacks and data breaches.

Check Point acquired Avanan, a cloud email and collaboration security company, in 2021. At the end of 2024, technological research and consulting firm Gartner recognized Check Point as a leader in the 2024 Gartner Magic Quadrant for Email Security Platforms.

10. Okta (NASDAQ:OKTA)

Company Profile

Market cap: US$14.64 billion
Share price: US$85.46

Okta is an identity and access management company that provides cloud software solutions for managing and securing user authentication, as well as building identity controls into applications, website services and devices. The company is investing in AI technologies to monitor customer signals and proactively identify potential risks.

Gartner recognized Okta as a Leader in the 2024 Gartner Magic Quadrant for Access Management for the eighth consecutive year.

FAQs for cybersecurity

Is cybersecurity a growing industry?

Cybersecurity is a growing industry — according to Statista, it has a projected CAGR of 7.58 percent between 2025 and 2029, which will allow it to reach a market value of US$271.9 billion. The largest segment within the cybersecurity market is security services, while cloud security is forecast to experience the fastest growth.

What are the current trends in cybersecurity?

Today’s top trends in cybersecurity include improvements in preventing and mitigating attacks against cloud services, growth in internet of things devices, the integration of artificial intelligence and machine learning, multi-factor identification and the increasing threat of deepfakes. Cybersecurity companies addressing these current issues in the market may have an advantage in attracting investor attention.

Which cybersecurity stocks pay dividends?

Very few cybersecurity stocks pay dividends; however, Cisco Systems and Juniper Networks (NYSE:JNPR) are two companies that offer dividend payments to their shareholders. Both pay quarterly dividends, with Cisco sporting an annual dividend yield of 2.7 percent, while Juniper Networks comes in at 2.29 percent. The average annual dividend yield for companies in the overall technology sector is 3.2 percent.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

A former child star from Australia died when the Los Angeles wildfires ripped through his family’s Malibu estate in California earlier this week, according to his mother.

Rory Callum Sykes was at the family’s 17-acre Mount Malibu TV Studios estate, where he had his own cottage, when it burned down on January 8, his mother Shelley Sykes wrote on X Thursday.

Shelley Sykes described her son, who appeared on the 1998 British TV series “Kiddy Kapers,” as “beautiful” and “wonderful” and said she was “totally heart broken” by his death.

She said she had tried to put out the wildfire cinders on her property’s roof using a hose but couldn’t because the water wasn’t working.

“He said, ‘mom leave me’ and no mom can leave their kid. And I’ve got a broken arm, I couldn’t lift him, I couldn’t move him,” Sykes told Australia’s 10 News First.

Her son, 32, was born blind with cerebral palsy on July 29, 1992, and had become famous for his speeches on overcoming disability. He was the co-founder of Happy Charity, which according to its site offers, “Hope, Happiness & Health to those that are Hurting.”

“He overcame so much with surgeries and therapies to regain his sight and to be able to learn to walk. Despite the pain, he still enthused about traveling the world with me from Africa to Antarctica,” Shelley Sykes wrote on X.

She said her son was born in Britain but lived in Australia, then America. He was “a gift born on mine and his grandma’s birthday,” she wrote.

On his website, Sykes describes himself as a professional speaker and consultant for many companies including the Tony Robbins Foundation, and the Cerebral Palsy Alliance.

In an appearance with his mother on Australian television show “Mornings with Kerri-Anne” in 2003, he discussed going on a trip to the United States to speak at a Tony Robbins motivational conference.

“It doesn’t matter what happens to you in life, it’s what you do about it that counts,” he told viewers.

“The Department of Foreign Affairs and Trade is providing consular assistance to his family. Our thoughts are with them,” DFAT told 9News. “Owing to our privacy obligations we are unable to provide further comment.”

This post appeared first on cnn.com

Ukraine claimed Saturday to have struck one of Russia’s largest oil refineries in a drone attack, starting a fire at the facility more than 700 miles into Russian territory.

The attack on the Taneco refinery in the city of Nizhnekamsk, Tatarstan – one of the largest and most modern refineries in Russia – was the second time the facility had been struck by Ukrainian forces within the space of a year, according to Lieutenant Andrii Kovalenko, the head of Ukraine’s Center for Countering Disinformation.

Despite the footage, the press service of the Republic of Tatarstan denied there had been a fire at the plant, insisting instead that it had been carrying out a mock evacuation as a safety exercise and that the images of the glowing facility in fact showed “the work of the plant’s torches.”

The Taneco refinery has a refining capacity of over 16 million tons of oil per year and “plays a key role in supplying fuel to the Russian army,” according to the Ukrainian official Kovalenko.

“The destruction of refineries and oil depots directly affects Russia’s ability to wage an intense war,” he added.

Kovalenko said the refinery had also been hit in the spring of 2024, in an attack that damaged its primary processing unit.

The attack last April was at the time the farthest into Russian territory Ukraine had struck since the beginning of the war.

This post appeared first on cnn.com

When 35-year-old combat medic Tetyana Tsymbaliuk regained consciousness in the hospital room, she found her boyfriend waiting with a bunch of flowers. He proposed, but she declined. After a serious injury, her leg had been amputated; she worried about being a burden as a wife.

“I realized that before amputation, I was more attractive. I was not sure that I could find a way to fulfil my family role as a woman,” said Tsymbaliuk. It took her a long time to regain her confidence.

Tsymbaliuk says she was one of the first Ukrainian military amputees following the full-scale Russian invasion in 2022. Almost three years on, nearly 370,000 Ukrainian soldiers have been wounded. Thousands have lost one or more limbs.

While the government does not provide official figures on amputations, a state program issued prostheses to almost 20,000 people across 2023 and the first half of 2024, and many others were helped by private programs in Ukraine and abroad.

In the past two years, Ukraine has implemented protocols for physical and, to some degree, psychological rehabilitation for those injured in conflict. But sexual rehabilitation for people who have lost limbs or suffered other serious injuries has been largely overlooked.

Sex has long been a taboo topic in Ukraine. While modern Ukrainians are more open about sex than in the Soviet era, the topic is still an uncomfortable one for many.

“If I ask veterans about sex issues, they usually say that everything is okay. Only a few of them after a while, when they start to trust me, can talk about the problems they have,” Revunets said.

There are no protocols or recommendations for sexual rehabilitation on the official governmental level, she said, or even any mention of it.

“That’s important because the doctor is required to work according to protocol,” Revunets said. “Sexual rehabilitation is not specified anywhere, so the doctor can only take the initiative if he or she wants to do so. But most doctors aren’t ready to talk about it.”

It takes time even to persuade some doctors of its significance, Revunets said. “When I tell my colleagues about the importance of sexual rehabilitation, they look at me as if I’m crazy, (someone) who doesn’t understand what kind of serious injuries the patient has,” she said.

A good sexologist can help in many ways. Revunets is one of the very few sexologists in the country who works with the military. “I find out what exactly is wrong with the patient. I ask how the person feels. Depending on this, I give advice – it can be advice on how and what to do from a technical point of view, or what medications to take, or help psychologically.”

‘I was told to have sex, but no one told me how’

The war has resulted in an unprecedented number of people with injuries, a situation for which Ukraine was unprepared. The lack of any information on sexual rehabilitation has motivated the Ukrainian nonprofit Veteran Hub, which is specifically dedicated to supporting war veterans and their families, to study the topic.

In 2023, Veteran Hub researchers conducted 39 in-depth interviews with injured soldiers and their partners. Among other things, interviewees spoke anonymously about their sex lives after injury.

Researchers found that sex itself had changed for many. For example, after being injured, some respondents started to prepare for or plan sexual relations due to physical changes.

One of the veterans in a long-term relationship said of the doctors who treated him: “I was told to have sex, but no one told me how. If we’re talking about the technical part, it is very important.” He told researchers that without formal resources available to them, men were having to pass on information “by word of mouth.”

In response to the researchers’ findings, Veteran Hub created a guide for veterans on how to restore their sexual lives after being wounded.

“We saw that there was a great demand for this topic. After physical rehabilitation, people start asking themselves whether they will be able to swim in the sea, go skiing, go on dates, or have sex. And usually no one can answer these questions,” said Veteran Hub project manager Kateryna Skorohod.

Olga Serdyuk, the head of a sexual educational program at a network of rehabilitation centers called Recovery, said: “We need to understand that a wounded person works with different specialists – surgeons, physiotherapists, psychologists – on the way to rehabilitation. Because there is a lack of sexologists in Ukraine, those doctors must be ready for the person to open up to them and talk about sexual rehabilitation.”

To help widen their knowledge, Recovery launched a course called “Sexual Life” to train doctors and other professionals working with Ukrainian soldiers.

Serious injury changes the life of not only the veteran but also their partner, Serdyuk explained.

“For some reason, Ukrainian society believes that a good wife should take care of her husband on her own, even if there is an opportunity to get help. A woman becomes a carer. What kind of sex can we talk about then?” Serdyuk said, referring to how the pressures of full-time caring can lessen a couple’s capacity to explore paths to sexual fulfilment.

“Even if we are talking about complete dysfunction or missing genitals, a person (who’s been injured) can still have an orgasm with pleasure. You have to work with your fantasies, study your body.”

People need to learn to accept themselves in a new way, and believe in their integrity, their body, Serdyuk said.

Ukrainian ‘Bachelor’ stars double amputee

Discussions surrounding disabilities are increasingly cropping up in Ukraine as casualties rise.

Popular dating show “The Bachelor” has taken the discussion into the mainstream, with 26-year-old Ukrainian veteran Oleksandr Budko – who lost both his legs in the war – cast as the star of the latest season.

An episode with an intimate scene, shown in November, became one of the most popular in the season. According to data provided by Starlight Media, a Ukrainian broadcasting group, about 2.8 million people all around the country watched it, making it the most viewed program on the day it aired.

“We were concerned about how people would react to seeing a person’s body with visible amputations in such an intimate context. There is no representation of people living with injuries in Ukraine and we didn’t know how people would react to it. It was a big challenge. But it turned out well.”

Kalyna thinks the audience was interested, in part, because they realize that in this time of war their own loved ones could be injured at any moment.

On his Instagram page, Budko said he was not taking part in the show to convince anyone of anything or prove his “normality.”

“My prostheses or even sometimes a wheelchair are just a part of me, but not what defines me,” he posted. “The fact that I have a disability does not make me less worthy of love or a happy life. And this is important to understand.”

Budko also posted that his first experience of sex after injury “was not just sex, but a step back to life.”

Choosing life over suffering

Among those to attend Recovery’s “Sexual Life” course is Oleksandr Batalov. The unit infantry commander, who works as an osteopath in civil life, lost his leg in a fierce battle on the front line. He recalls that it took time for him to get used to his changed body.

“At the beginning, with such trauma, you want no one to look at you. But my wife gave me huge support. So, I got a grip. I chose life, not suffering,” he said. The psychologist helped a lot, he added.

There are very few sexologists in the hospitals, he said, but men who have experienced serious injuries are talking about sex with one another, and that’s important. However, “they need to have specialists they can talk to” as well, Batalov said.

That’s why he is starting this course. “If you survived, you have to live. Despite the injury, my life is full and interesting, I want to leave and study and share the knowledge,” said Batalov, who is now working again as an osteopath.

The same goes for Tsymbaliuk, the injured combat medic. She decided to live a fulfilling life no matter what. Her boyfriend did not give up and proposed again.

After months of rehabilitation in Germany, and later in Ukraine’s Superhumans Center, she finally married him, realizing “she was full of love that she wanted to fulfil.” Four months ago, they welcomed their first child together.

“I’m not hiding my prosthetic. I’m living a full life. And I’m happy,” she said.

This post appeared first on cnn.com

Sudan’s army said on Saturday it had entered the central city of Wad Madani and was pushing out its paramilitary rivals the Rapid Support Forces (RSF), a step which if completed successfully would be its biggest gain in near two years of war.

The army posted a video appearing to show troops inside the city, which is the capital of El Gezira state, an agricultural and trading hub that has been held by the RSF since December 2023.

Recapture of the state as a whole could mark a turning point in the war that began in April 2023 over disputes on the integration of the two forces, which has created one of the world’s largest humanitarian crises with the displacement of more than 12 million people and half the population facing hunger.

“The leadership of the Armed Forces congratulates our people on the entry of our forces into Wad Madani this morning. They are now working to clean up the remaining rebel pockets inside the city,” an army statement said.

The state, located in the center of the country and south of the capital Khartoum has seen some of the RSF’s bloodiest attacks on civilians, as well as the burning of fields, looting of hospitals and markets, and flooding of irrigation ditches.

Despite a long history as an agricultural trade hub, Madani has been marked by experts as an area at risk of famine due to the blockades imposed as part of the conflict.

The army had stepped up its campaign to retake El Gezira in recent months, after retaking Sennar state in the south, including by increasing airstrikes that have often hit civilians.

The RSF’s top commander in the state defected to the army in October, and his troops took part in Saturday’s operations, though the RSF responded at the time with a series of attacks.

The army also on Saturday continued its operations on the city of Bahri, part of the greater capital, where it has also made advances in recent months.

The RSF controls most of the west of the country, where it is fighting the army for al-Fashir, its last stronghold in the Darfur region. The two forces are also actively fighting over White Nile state in the south of the country.

This post appeared first on cnn.com